Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Current Opinion in Infectious Diseases

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?

View Full Paper
Ask AI
Bookmark
Share

Authors

CBCecilia BonazzettiMGMaddalena GiannellaRPRenato Pascale

Discussion

Loading...

Member takes

Overview

Review highlights treatment strategies for carbapenem-resistant Acinetobacter baumannii, suggesting combination therapy with imipenem may enhance efficacy.

Key Points

  • Combination therapy of sulbactam-durlobactam is preferred for critically ill patients with CRAB infections.
  • Registration trial confirms sulbactam-durlobactam is effective, showing good tolerance in treating CRAB infections.
  • Microbiological data indicate potential synergistic effects when combining sulbactam-durlobactam with carbapenems.
  • Future studies need to evaluate the efficacy comparisons between monotherapy and combination regimens for CRAB.

Cite This Study

Bonazzetti et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478bfc7https://doi.org/10.1097/qco.0000000000001148
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam2025
  2. 2Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report2025
  3. 3P40 Evaluation of sulbactam/durlobactam activity against carbapenem-resistant <i>Acinetobacter baumannii</i> in India: an institutional experience2025
  4. 4<i>In vitro</i> efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian <i>Mycobacterium abscessus</i> isolates2025 · 1 citations
  5. 5 activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant 2025